Warfarin remains a widely prescribed oral anticoagulant despite its narrow therapeutic index and its association with life-threatening bleeding events. This systematic review examined the impact of clinical risk factors on international normalized ratio (INR) control in patients receiving Warfarin therapy. Following the PRISMA-P guidelines, we searched four electronic databases (PubMed, SCOPUS, Embase, and Web of Science) using Medical Subject Headings to identify eligible cohort studies published between 2016 and 2020. A total of 15 original research articles met the inclusion criteria. The risk of bias was assessed using the Newcastle-Ottawa scale. This review identified several clinical risk factors influencing INR control, including drug interactions with Warfarin, herbal supplements, dietary intake of vitamin K, and multiple comorbidities (anemia, heart failure, chronic kidney disease, psychiatric disorders, prosthetic valve), kidney transplant recipient, hemodialysis, and hypoalbuminemia. These clinical risk factors adversely affect the time in therapeutic range, thereby increasing the risk of adverse outcomes such as thromboembolism, major bleeding, and mortality. Overall, these clinical risk factors compromise Warfarin efficacy by contributing to subtherapeutic or supratherapeutic INR levels. Identifying and addressing these clinical risk factors prior to initiating Warfarin therapy is essential to achieving optimal INR control.
Cite this paper
Ramasamy, T. , Jahan, N. K. , Pillai, N. and Yap, C. G. (2025). Influence of Clinical Risk Factors on International Normalized Ratio Control in Patients on Warfarin Therapy: A Systematic Review. Open Access Library Journal, 12, e13567. doi: http://dx.doi.org/10.4236/oalib.1113567.
Hirsh, J., Fuster, V., Ansell, J. and Halperin, J.L. (2003) American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation, 107, 1692-1711. https://doi.org/10.1161/01.cir.0000063575.17904.4e
Holbrook, A.M. (2005) Systematic Overview of Warfarin and Its Drug and Food Interactions. Archives of Internal Medicine, 165, 1095-1106. https://doi.org/10.1001/archinte.165.10.1095
Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., et al. (2014) Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet, 383, 955-962. https://doi.org/10.1016/s0140-6736(13)62343-0
Merli, G.J. and Tzanis, G. (2008) Warfarin: What Are the Clinical Implications of an Out-of-Range-Therapeutic International Normalized Ratio? Journal of Thrombosis and Thrombolysis, 27, 293-299. https://doi.org/10.1007/s11239-008-0219-9
Rose, A.J., Berlowitz, D.R., Ash, A.S. and Ozonoff, A. (2011) The Persistence of Warfarin Treatment Disparities in the VA Healthcare System. The American Journal of Managed Care, 17, 548-554.
Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., et al. (2013) Vitamin K Antagonists in Heart Disease: Current Status and Perspectives (Section III). Thrombosis and Haemostasis, 110, 1087-1107. https://doi.org/10.1160/th13-06-0443
Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G., et al. (2008) Benefit of Oral Anticoagulant over Antiplatelet Ther-apy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Coun-tries as Measured by Time in Therapeutic Range. Circulation, 118, 2029-2037. https://doi.org/10.1161/circulationaha.107.750000
Piccini, J.P., Hellkamp, A.S., Lokhnygina, Y., Patel, M.R., Harrell, F.E., Singer, D.E., et al. (2014) Relationship between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial. Journal of the American Heart Association, 3, e000521. https://doi.org/10.1161/jaha.113.000521
Mearns, E.S., Kohn, C.G., Song, J., Hawthorne, J., Meng, J., White, C.M., et al. (2014) Meta-Analysis to Assess the Quality of International Nor-malized Ratio Control and Associated Outcomes in Venous Thromboembolism Patients. Thrombosis Research, 134, 310-319. https://doi.org/10.1016/j.thromres.2014.05.035
Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009) Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 361, 1139-1151. https://doi.org/10.1056/nejmoa0905561
Eikelboom, J.W., Connolly, S.J., Brueckmann, M., Granger, C.B., Kappetein, A.P., Mack, M.J., et al. (2013) Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine, 369, 1206-1214. https://doi.org/10.1056/nejmoa1300615
Ageno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M. and Palareti, G. (2012) Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e44S-e88S. https://doi.org/10.1378/chest.11-2292
Ramasamy, T., Pillai, N.K., Yap, C.G. and Jahan, N.K. (2020) Non-Clinical Factors Associated with International Normalized Ratio Control in Patients on Warfarin Therapy: A Re-view Paper. Open Access Library (OALib), 7, e6947. https://doi.org/10.4236/oalib.1106947
Wigle, P., Hein, B., Bloomfield, H. E., Tubb, M. and Doherty, M. (2013) Updated Guidelines on Outpatient Anticoagulation. American Family Physician, 87, 556-566.
Stang, A. (2010) Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. European Journal of Epidemiology, 25, 603-605. https://doi.org/10.1007/s10654-010-9491-z
Al-Momany, N.H., Makahleh, Z.M., Al-Omari, N.A., Al-Sarayreh, H.A. and Momani, R.O. (2019) Analysis of Factors That Interrupt with INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients. Clinical and Applied Thrombosis/Hemostasis, 25, 1-9. https://doi.org/10.1177/1076029619870252
Botton, M.R., Viola, P.P., Meireles, M.R., Bruxel, E.M., Zuchinali, P., Bandinelli, E., et al. (2020) Identification of Environmental and Genetic Factors That Influence Warfarin Time in Therapeu-tic Range. Genetics and Molecular Biology, 43, e20190025. https://doi.org/10.1590/1678-4685-gmb-2019-0025
Jaakkola, S., Nuotio, I., Kiviniemi, T.O., Virtanen, R., Issa-koff, M. and Airaksinen, K.E.J. (2017) Incidence and Predictors of Excessive Warfarin Anticoagulation in Patients with Atrial Fibrillation—The EWA Study. PLOS ONE, 12, e0175975. https://doi.org/10.1371/journal.pone.0175975
Bertram, V., Yeo, K., Anoopkumar-Dukie, S. and Bernaitis, N. (2019) Proton Pump Inhibitors Co-Prescribed with Warfarin Reduce Warfarin Control as Measured by Time in Therapeutic Range. International Journal of Clinical Practice, 73, e13382. https://doi.org/10.1111/ijcp.13382
Liang, H., Du, X., Zhou, Y., Yang, X., Xia, S., Dong, J., et al. (2019) Control of An-ticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. Medical Science Monitor, 25, 4691-4698. https://doi.org/10.12659/msm.917131
Björck, F., Kadhim, H. and Själander, A. (2018) Predictors for INR-Control in a Well-Managed Warfarin Treatment Setting. Journal of Thrombosis and Thrombolysis, 47, 227-232. https://doi.org/10.1007/s11239-018-1765-4
Prochaska, J.H., Hausner, C., Nagler, M., Göbel, S., Eggebrecht, L., Panova-Noeva, M., et al. (2019) Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service. Thrombosis and Haemostasis, 119, 1347-1357. https://doi.org/10.1055/s-0039-1692175
Szummer, K., Gasparini, A., Eliasson, S., ärnlöv, J., Qureshi, A.R., Bárány, P., et al. (2017) Time in Therapeutic Range and Outcomes after Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients with Renal Dysfunction. Journal of the American Heart Association, 6, e004925. https://doi.org/10.1161/jaha.116.004925
Inoue, H., Kodani, E., Atarashi, H., Okumura, K., Yamashita, T. and Ori-gasa, H. (2018) Renal Dysfunction Affects Anticoagulation Control with Warfarin and Outcomes in Japanese Elderly Patients with Non-Valvular Atrial Fibrillation. Circulation Journal, 82, 2277-2283. https://doi.org/10.1253/circj.cj-18-0242
Yanik, M.V., Irvin, M.R., Beasley, T.M., Jacobson, P.A., Julian, B.A. and Limdi, N.A. (2017) Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 37, 1366-1373. https://doi.org/10.1002/phar.2032
Kawai, M., Harada, M., Motoike, Y., Koshikawa, M., Ichikawa, T., Watanabe, E., et al. (2019) Impact of Serum Albumin Levels on Supratherapeutic PT-INR Control and Bleeding Risk in Atrial Fibrillation Pa-tients on Warfarin: A Prospective Cohort Study. IJC Heart & Vasculature, 22, 111-116. https://doi.org/10.1016/j.ijcha.2019.01.002
Rikala, M., Hauta-Aho, M., Helin-Salmivaara, A., Lassila, R., Korhonen, M.J. and Huupponen, R. (2015) Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy—A Popula-tion-Based Register Study. Basic & Clinical Pharmacology & Toxicology, 117, 126-132. https://doi.org/10.1111/bcpt.12373
Rettie, A.E., Korzekwa, K.R., Kunze, K.L., Lawrence, R.F., Eddy, A.C., Aoyama, T., et al. (1992) Hydroxylation of Warfarin by Human cDNA-Expressed Cytochrome P-450: A Role for P-4502C9 in the Etiology of (S)-Warfarin-Drug Interactions. Chemical Research in Toxicology, 5, 54-59. https://doi.org/10.1021/tx00025a009
Kaminsky, L.S. and Zhang, Z. (1997) Human P450 Metabolism of Warfarin. Pharmacology & Therapeutics, 73, 67-74. https://doi.org/10.1016/s0163-7258(96)00140-4
Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., et al. (2005) The Impact of CYP2C9 and VKORC1 Genetic Polymor-phism and Patient Characteristics upon Warfarin Dose Requirements: Proposal for a New Dosing Regimen. Blood, 106, 2329-2333. https://doi.org/10.1182/blood-2005-03-1108
Wadelius, M. and Pirmohamed, M. (2006) Pharmaco-genetics of Warfarin: Current Status and Future Challenges. The Pharmacogenomics Journal, 7, 99-111. https://doi.org/10.1038/sj.tpj.6500417
Martín-Pérez, M., Gaist, D., de Abajo, F. and García Rodríguez, L. (2018) Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case-Control Study in a Pri-mary Health Care Database. Thrombosis and Haemostasis, 119, 66-76. https://doi.org/10.1055/s-0038-1676519
Lee, A. and Crowther, M. (2011) Practical Issues with Vitamin K Antagonists: Elevated INRs, Low Time-in-Therapeutic Range, and Warfarin Fail-ure. Journal of Thrombosis and Thrombolysis, 31, 249-258. https://doi.org/10.1007/s11239-011-0555-z
Boyce, M.L., Zayac, A., Davis, A., Badrick, T., Anoopkumar-Dukie, S. and Bernaitis, N. (2018) Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range. Basic & Clinical Pharmacology & Toxicology, 123, 504-508. https://doi.org/10.1111/bcpt.13037
Okumura, K., Komatsu, T., Yamashita, T., Okuyama, Y., Harada, M., Konta, Y., et al. (2011) Time in the Therapeutic Range during Warfarin Therapy in Japanese Patients with Non-Valvular Atrial Fibrilla-tion—A Multicenter Study of Its Status and Influential Factors. Circulation Journal, 75, 2087-2094. https://doi.org/10.1253/circj.cj-11-0350
Mueller, S., Pfannkuche, M., Breithardt, G., Bauersachs, R., Maywald, U., Kohlmann, T., et al. (2014) The Quality of Oral Anticoagulation in General Practice in Patients with Atrial Fibrillation. Euro-pean Journal of Internal Medicine, 25, 247-254. https://doi.org/10.1016/j.ejim.2013.12.013
Heimark, L.D., Wien-kers, L., Kunze, K., Gibaldi, M., Eddy, A.C., Trager, W.F., et al. (1992) The Mechanism of the Interaction between Amioda-rone and Warfarin in Humans. Clinical Pharmacology and Therapeutics, 51, 398-407. https://doi.org/10.1038/clpt.1992.39
Macedo, A.F., Bell, J., McCarron, C., Conroy, R., Richardson, J., Scowcroft, A., et al. (2015) Determinants of Oral Anticoagulation Con-trol in New Warfarin Patients: Analysis Using Data from Clinical Practice Research Datalink. Thrombosis Research, 136, 250-260. https://doi.org/10.1016/j.thromres.2015.06.007
Wedemeyer, R. and Blume, H. (2014) Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Safety, 37, 201-211. https://doi.org/10.1007/s40264-014-0144-0
Ge, B., Zhang, Z. and Zuo, Z. (2014) Updates on the Clinical Evidenced Herb‐warfarin Interactions. Evidence-Based Complementary and Alternative Medicine, 2014, Article ID: 957362. https://doi.org/10.1155/2014/957362
Rouaud, A., Hanon, O., Boureau, A., Chapelet, G.G. and de Decker, L. (2015) Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation: A French National Cross-Sectional Study. PLOS ONE, 10, e0119043. https://doi.org/10.1371/journal.pone.0119043
DeRemer, C.E., McMichael, B. and Young, H.N. (2018) Warfarin Patients with Anemia Show Trend of Out-of-Range International Normalized Ratio Frequency with Point-of-Care Testing in an Anticoagulation Clinic. Journal of Pharmacy Practice, 32, 499-502. https://doi.org/10.1177/0897190018768114
Cohen, J., Wang, J.J., Sinvani, L., Kozikowski, A., Qiu, G., Pekmezaris, R., et al. (2019) Quality Metrics of Warfarin Initiation in Hospitalized Older Adults. Journal of Thrombosis and Thrombo-lysis, 48, 459-465. https://doi.org/10.1007/s11239-019-01905-x
García-Sempere, A., Hurtado, I., Bejara-no-Quisoboni, D., Rodríguez-Bernal, C., Santa-Ana, Y., Peiró, S., et al. (2019) Quality of INR Control and Switching to Non-Vitamin K Oral Anticoagulants between Women and Men with Atrial Fibrillation Treated with Vitamin K Antagonists in Spain. A Population-Based, Real-World Study. PLOS ONE, 14, e0211681. https://doi.org/10.1371/journal.pone.0211681
Visser, L.E., Bleumink, G.S., Trienekens, P.H., Vulto, A.G., Hofman, A. and Stricker, B.H.C. (2004) The Risk of Overanticoagulation in Patients with Heart Failure on Coumarin Anticoagulants. British Journal of Haematology, 127, 85-89. https://doi.org/10.1111/j.1365-2141.2004.05162.x
Vahanian, A., Al-fieri, O., Andreotti, F., Antunes, M.J., Barón-Esquivias, G., Baumgartner, H., Borger, M.A., Carrel, T.P. and De Bonis, M. (2012) Guidelines on the Management of Valvular Heart Disease (Version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 33, 2451-2496.
Mvondo, C.M., Pugliese, M., Ambassa, J.C., Giamberti, A., Bovio, E. and Dailor, E. (2018) Mechanical Heart Valve Replacement in a Low-Middle Income Region in the Modern Era: Midterm Results from a Sub-Saharan Center. The Thoracic and Cardiovascular Surgeon, 68, 099-106. https://doi.org/10.1055/s-0038-1666873
Buchanan-Leel, B., Levetan, B.N., Lombard, C.J. and Commerford, P.J. (2002) Fixed-Dose versus Adjusted-Dose Warfarin in Patients with Prosthetic Heart Valves in a Peri-Urban Impoverished Population. The Journal of Heart Valve Disease, 11, 583-592.
Chalachew, T., Yadeta, D. and Tefera, E. (2019) Factors Associated with Sub-Optimal Control of Anticoagulation in Patients with Prosthetic Heart Valves Taking Oral Anticoagulants in a Sub-Saharan African Setting. Cardiovascular Journal of Africa, 30, 317-320. https://doi.org/10.5830/cvja-2019-024
Michal, M., Prochaska, J.H., Ullmann, A., Keller, K., Gobel, S., Coldewey, M., et al. (2014) Relevance of Depression for Anticoagulation Management in a Routine Medical Care Setting: Results from the Thrombeval Study Program. Journal of Thrombosis and Haemostasis, 12, 2024-2033. https://doi.org/10.1111/jth.12743
Michal, M., Prochaska, J.H., Keller, K., Göbel, S., Coldewey, M., Ullmann, A., et al. (2015) Symptoms of Depression and Anxiety Predict Mortality in Patients Undergoing Oral Anticoagulation: Results from the Thrombeval Study Program. International Journal of Cardiology, 187, 614-619. https://doi.org/10.1016/j.ijcard.2015.03.374
O’Byrne, S., Barry, M.G., Collins, W.C.J., O'Connor, P., Cullen, M.J. and Feely, J. (1993) Plasma Protein Binding of Lidocaine and Warfarin in Insulin-Dependent and Non-Insulin-Dependent Dia-betes Mellitus. Clinical Pharmacokinetics, 24, 183-186. https://doi.org/10.2165/00003088-199324020-00007
Dahal, K., Kunwar, S., Rijal, J., Schulman, P. and Lee, J. (2016) Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users with Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest, 149, 951-959. https://doi.org/10.1378/chest.15-1719
Limdi, N.A., Beasley, T.M., Baird, M.F., Goldstein, J.A., McGwin, G., Arnett, D.K., et al. (2009) Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications. Journal of the American Society of Nephrology, 20, 912-921. https://doi.org/10.1681/asn.2008070802
Limdi, N.A., Nolin, T.D., Booth, S.L., Centi, A., Marques, M.B., Crowley, M.R., et al. (2015) Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study. American Journal of Kidney Diseases, 65, 701-709. https://doi.org/10.1053/j.ajkd.2014.11.004
Odar-Cederlof, I. (1977) Plasma Protein Binding of Phenytoin and Warfarin in Patients Undergoing Renal Transplantation. Clinical Pharma-cokinetics, 2, 147-153. https://doi.org/10.2165/00003088-197702020-00005
Kleinow, M.E., Garwood, C.L., Clemente, J.L. and Whittaker, P. (2011) Effect of Chronic Kidney Disease on Warfarin Management in a Pharma-cist-Managed Anticoagulation Clinic. Journal of Managed Care Pharmacy, 17, 523-530. https://doi.org/10.18553/jmcp.2011.17.7.523
Chan, K.E., Lazarus, J.M., Thadhani, R. and Hakim, R.M. (2009) War-farin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. Journal of the American Society of Nephrology, 20, 2223-2233. https://doi.org/10.1681/asn.2009030319
Kai, B., Bogorad, Y., Nguyen, L.N., Yang, S., Chen, W., Spencer, H.T., et al. (2017) Warfarin Use and the Risk of Mortality, Stroke, and Bleeding in Hemodialysis Patients with Atrial Fibrillation. Heart Rhythm, 14, 645-651. https://doi.org/10.1016/j.hrthm.2017.01.047
Mitsuma, W., Matsubara, T., Hatada, K., Imai, S., Saito, N., Shimada, H., et al. (2016) Clinical Characteristics of Hemodialysis Patients with Atrial Fibrillation: The RAKUEN (Registry of Atrial Fibrillation in Chronic Kidney Disease under Hemodialysis from Niigata) Study. Journal of Cardiology, 68, 148-155. https://doi.org/10.1016/j.jjcc.2015.08.023
Lentine, K.L., Schnitzler, M.A., Abbott, K.C., Li, L., Xiao, H., Burroughs, T.E., et al. (2006) Incidence, Predictors, and Associated Outcomes of Atrial Fibrillation after Kidney Transplantation. Clinical Journal of the American Society of Nephrology, 1, 288-296. https://doi.org/10.2215/cjn.00920805
Lenihan, C.R., Montez-Rath, M.E., Scandling, J.D., Turakhia, M.P. and Winkelmayer, W.C. (2013) Outcomes after Kidney Transplantation of Patients Previously Diagnosed with Atrial Fibrillation. American Journal of Transplantation, 13, 1566-1575. https://doi.org/10.1111/ajt.12197
Abdelhafiz, A.H., Myint, M.P., Tayek, J.A. and Wheeldon, N.M. (2009) Anemia, Hypoalbuminemia, and Renal Impairment as Predictors of Bleeding Complications in Patients Receiving Anticoagulation Therapy for Nonvalvular Atrial Fibrillation: A Secondary Analysis. Clinical Therapeutics, 31, 1534-1539. https://doi.org/10.1016/j.clinthera.2009.07.015
